RxDoctor Payments DataLook up a doctor →

Sabila Shah

Nurse Practitioner · Amherst, NYNPI 1407413248

Payments from drug & device makers

$21,834in general payments, 2019–2025

Across 1,078 payments — averaging $20.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Teva Pharmaceuticals USA, Inc.$3K
  • Abbott$3K
  • UCB, Inc.$1K
  • Neurocrine Biosciences, Inc.$1K
  • Novartis$873
  • plus $10K from 54 others

What the payments were for

  • Consulting fees$5402%
  • Travel & lodging$1,6928%
  • Food & beverage$19,34489%
  • Education$2591%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)158$3,350
Teva Pharmaceuticals USA, Inc.147$2,715
Abbott30$2,704
UCB, Inc.50$1,040
Neurocrine Biosciences, Inc.63$1,037
Novartis68$873
Amgen(2 entities)36$855
SK Life Science, Inc.27$727
AstraZeneca(2 entities)34$608
Amneal Pharmaceuticals LLC58$589
Lundbeck LLC31$479
Acadia Pharmaceuticals Inc51$449
Kyowa Kirin, Inc.25$417
Axsome Therapeutics, Inc.17$370
Livanova USA, Inc.8$368
Adamas Pharmaceuticals, Inc.15$348
Tanabe Pharma America, Inc.18$308
MDD US Operations, LLC19$297
Merz Pharmaceuticals, LLC13$291
Otsuka America Pharmaceutical, Inc.15$288
Catalyst Pharmaceuticals, Inc.14$279
Jazz Pharmaceuticals Inc.6$249
Alnylam Pharmaceuticals Inc.15$237
GRT US Holding, Inc.10$208
Lilly USA, LLC9$178
CSL Behring9$170
Pfizer10$167
Neurelis, Inc.4$162
Johnson & Johnson11$149
Biogen4$145
Greenwich Biosciences, Inc.17$137
EMD Serono, Inc.1$127
Inspire Medical Systems, Inc.2$118
Harmony Biosciences LLC4$96
Octapharma USA, Inc.5$85
Supernus Pharmaceuticals, Inc.5$76
Argenx US, Inc.4$72
Banner Life Sciences, LLC5$70
Eisai Inc.4$68
GE HealthCare8$65
Scilex Pharmaceuticals Inc.4$65
Averitas Pharma Inc.3$63
Idorsia Pharmaceuticals US Inc4$63
Takeda Pharmaceuticals U.S.A., Inc.3$61
Mallinckrodt Hospital Products Inc.3$56
Avanir Pharmaceuticals, Inc.2$52
Impel Pharmaceuticals Inc.3$51
Biohaven Pharmaceutical Holding Company Ltd.3$50
Ipsen Biopharmaceuticals, Inc3$50
Acorda Therapeutics, Inc2$40
Grifols USA, LLC2$39
TG Therapeutics, Inc.2$38
Kedrion Biopharma, Inc.2$37
Biohaven Pharmaceuticals, Inc.3$35
Intrabio Inc1$32
Upsher-smith Laboratories LLC1$26
Sanofi2$25
Biomarin Pharmaceutical Inc.1$25
Bristol Myers Squibb1$21
Akcea Therapeutics, Inc.1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$21,834 in reported general payments places this provider in the 95th percentile of 4,112 nurse practitioner providers in New York.

See all nurse practitioner providers in New York

Medicare billing

Part B allowed, 2024
$76,096
Medicare patients
293
Services billed
4,299

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AustedoDeutetrabenazine64$696,211
IngrezzaValbenazine Tosylate54$413,318
NuplazidPimavanserin Tartrate76$408,194
Droxidopa44$211,198
Austedo XrDeutetrabenazine12$148,981
RytaryCarbidopa/Levodopa36$67,968
Nurtec OdtRimegepant Sulfate43$60,251
Carbidopa-LevodopaCarbidopa/Levodopa1,107$53,828
Rasagiline Mesylate201$52,714
Tetrabenazine14$41,880
UbrelvyUbrogepant23$31,683
QuliptaAtogepant19$23,869
XcopriCenobamate11$18,858
Primidone531$14,363
Topiramate ErTopiramate24$13,993

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo, Austedo Xr$2,715$845,19276 claims
Neurocrine Biosciences, Inc.Ingrezza, Ongentys$1,037$421,12166 claims
Acadia Pharmaceuticals IncNuplazid$449$408,19476 claims
Amneal Pharmaceuticals LLCRytary$589$67,96836 claims
PfizerNurtec Odt$167$60,25143 claims
AbbVieUbrelvy, Qulipta$3,350$55,55242 claims
SK Life Science, Inc.Xcopri$727$18,85811 claims
Upsher-smith Laboratories LLCTopiramate$26$3,087265 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,112 nurse practitioner providers in New York.

Other nurse practitioner in Amherst

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →